Rajeev Ramchandran
Concepts (85)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Retinal Vein Occlusion | 1 | 2008 | 3 |
Why?
|
Fluocinolone Acetonide | 1 | 2008 | 3 |
Why?
|
Macular Edema | 1 | 2008 | 6 |
Why?
|
Glucocorticoids | 2 | 2008 | 107 |
Why?
|
Drug Delivery Systems | 1 | 2008 | 55 |
Why?
|
Saccades | 1 | 2004 | 19 |
Why?
|
Reaction Time | 1 | 2004 | 81 |
Why?
|
Photic Stimulation | 1 | 2004 | 58 |
Why?
|
Schizophrenia | 1 | 2004 | 48 |
Why?
|
Neoplasm Proteins | 2 | 1999 | 110 |
Why?
|
Intermediate Filament Proteins | 1 | 1999 | 17 |
Why?
|
Microtubule-Associated Proteins | 1 | 1999 | 33 |
Why?
|
Peptide Fragments | 2 | 1998 | 144 |
Why?
|
Neovascularization, Physiologic | 1 | 1999 | 68 |
Why?
|
Collagen | 1 | 1999 | 118 |
Why?
|
Fluorescein Angiography | 2 | 2008 | 19 |
Why?
|
Retinal Vasculitis | 1 | 2009 | 3 |
Why?
|
Retinal Artery | 1 | 2009 | 12 |
Why?
|
Blindness | 1 | 2009 | 22 |
Why?
|
Eosinophilia | 1 | 2009 | 24 |
Why?
|
Retinal Diseases | 1 | 2009 | 22 |
Why?
|
Drug Implants | 1 | 2008 | 15 |
Why?
|
Vitreous Body | 1 | 2008 | 14 |
Why?
|
Fovea Centralis | 1 | 2008 | 9 |
Why?
|
Intraocular Pressure | 1 | 2008 | 22 |
Why?
|
Tomography, Optical Coherence | 1 | 2008 | 10 |
Why?
|
Visual Acuity | 1 | 2008 | 46 |
Why?
|
Pilot Projects | 1 | 2008 | 264 |
Why?
|
Chronic Disease | 1 | 2008 | 267 |
Why?
|
Prospective Studies | 1 | 2008 | 545 |
Why?
|
Follow-Up Studies | 1 | 2008 | 553 |
Why?
|
Analysis of Variance | 1 | 2004 | 339 |
Why?
|
Sequence Homology, Amino Acid | 2 | 1999 | 156 |
Why?
|
Cloning, Molecular | 2 | 1999 | 183 |
Why?
|
Dermis | 1 | 2000 | 6 |
Why?
|
Herpesvirus 2, Human | 1 | 2000 | 7 |
Why?
|
Basement Membrane | 1 | 2000 | 31 |
Why?
|
Treatment Outcome | 1 | 2008 | 661 |
Why?
|
Male | 3 | 2004 | 1553 |
Why?
|
Herpes Simplex | 1 | 2000 | 31 |
Why?
|
Collagen Type XVIII | 1 | 1999 | 3 |
Why?
|
Epidermis | 1 | 2000 | 30 |
Why?
|
Endostatins | 1 | 1999 | 5 |
Why?
|
Herpesvirus 1, Human | 1 | 2000 | 28 |
Why?
|
Humans | 5 | 1999 | 1856 |
Why?
|
Transplantation, Heterologous | 1 | 1999 | 57 |
Why?
|
Female | 3 | 2000 | 1643 |
Why?
|
Laminin | 1 | 1998 | 40 |
Why?
|
Amino Acid Sequence | 2 | 1999 | 319 |
Why?
|
Metalloendopeptidases | 1 | 1998 | 25 |
Why?
|
Neoplasms, Experimental | 1 | 1999 | 72 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2001 | 119 |
Why?
|
Molecular Sequence Data | 2 | 1999 | 404 |
Why?
|
Cell Movement | 1 | 1999 | 163 |
Why?
|
Membrane Proteins | 1 | 2001 | 233 |
Why?
|
Cell Division | 1 | 1999 | 273 |
Why?
|
Recombinant Proteins | 1 | 1999 | 290 |
Why?
|
Cell Line | 1 | 1999 | 375 |
Why?
|
Antineoplastic Agents | 1 | 1999 | 190 |
Why?
|
Adult | 1 | 2004 | 1317 |
Why?
|
Vision, Monocular | 1 | 2009 | 8 |
Why?
|
Vasoconstriction | 1 | 2009 | 37 |
Why?
|
Arterioles | 1 | 2009 | 14 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2009 | 27 |
Why?
|
Prednisone | 1 | 2009 | 80 |
Why?
|
Drug Therapy, Combination | 1 | 2009 | 189 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2009 | 85 |
Why?
|
Anticoagulants | 1 | 2009 | 88 |
Why?
|
Subtraction Technique | 1 | 2001 | 13 |
Why?
|
Mice, Inbred ICR | 1 | 2001 | 34 |
Why?
|
Nucleic Acid Hybridization | 1 | 2001 | 94 |
Why?
|
DNA Primers | 1 | 2001 | 208 |
Why?
|
Gelatinases | 1 | 1998 | 4 |
Why?
|
Neurites | 1 | 1998 | 15 |
Why?
|
Mice | 2 | 2000 | 623 |
Why?
|
Animals | 3 | 1998 | 1031 |
Why?
|
PC12 Cells | 1 | 1998 | 27 |
Why?
|
Mice, Inbred BALB C | 1 | 2000 | 176 |
Why?
|
Immunohistochemistry | 1 | 2001 | 355 |
Why?
|
Extracellular Matrix | 1 | 1998 | 79 |
Why?
|
Base Sequence | 1 | 2001 | 371 |
Why?
|
Disease Models, Animal | 1 | 2000 | 349 |
Why?
|
Middle Aged | 1 | 2009 | 1161 |
Why?
|
RNA, Messenger | 1 | 2001 | 394 |
Why?
|
Rats | 1 | 1998 | 530 |
Why?
|
